Stock CTNM CONTINEUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
15.32 USD +2.13% Intraday chart for Contineum Therapeutics, Inc. -2.79% -.--%
May. 20 Contineum Therapeutics, Inc. Appoints Troy Ignelzi as Independent Member of Its Board of Directors and as Chair of the Audit Committee CI
Apr. 30 Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Morgan Stanley Starts Contineum Therapeutics With Overweight Rating
MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target
MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTNM Stock
  4. News Contineum Therapeutics, Inc.
  5. Analyst Reco.